thiazoles has been researched along with Granulocytic Leukemia, Chronic in 603 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.17) | 18.7374 |
| 1990's | 3 (0.50) | 18.2507 |
| 2000's | 228 (37.81) | 29.6817 |
| 2010's | 365 (60.53) | 24.3611 |
| 2020's | 6 (1.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akgun-Cagliyan, G; Cort-Donmez, A; Guner, E; Hanikoglu, F; Kilic-Toprak, E; Olgen, S; Tunc-Ata, M | 1 |
| Abad-Santos, F; Carvoeiro, DC; Cuesta-Mateos, C; Del Campo, L; Gómez-García de Soria, V; Laganá, C; Marcos-Jiménez, A; Muñoz-Calleja, C; Roy-Vallejo, E; Ruef, N; Stein, JV; Villapalos-García, G; Zubiaur, P | 1 |
| De Lavallade, H; Dillon, R; Green, A; Harrington, P; Harrison, C; Hussain, F; Kordasti, S; McLornan, DP; Ong, M; Radia, D; Raj, K; Rousselot, P; Verde, A | 1 |
| Bakhshi, S; Pushpam, D | 1 |
| Huang, YC; Jiang, S; Liu, J; Lu, YZ; Sun, XY; Wang, GZ; Wang, M; Zhang, KJ; Zhou, GB; Zhou, YC | 1 |
| Cantonetti, M; Cattel, F; Celeste, MG; Colasanto, I; Costantini, A; de Rosa, C; Di Biagio, K; Federici, F; Franceschini, L; Frazzetto, A; La Barba, G; Lanzillo, R; Luciano, L; Monteverde, M; Musicco, F; Pane, F; Pasquazi, A; Ranucci, E; Rizzo, M; Rossi, C; Santoleri, F; Scaldaferri, M; Scortechini, AR; Torquati, G; Vozza, A | 1 |
| Dalal, H; Damodar, S; Gowda, DA; H, K; Subramanian, S; V P, S; Vyas, N | 1 |
| Capitani, S; Celeghini, C; Evangelisti, C; Marisi, G; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Ulivi, P; Ultimo, S; Zauli, G | 1 |
| Eskazan, AE | 1 |
| Noronha, S; Sawyer, S | 1 |
| Koutna, I; Mayer, J; Potesil, D; Potesilova, M; Simara, P; Stejskal, S; Tesarova, L; Zdrahal, Z | 1 |
| Aung, T; Beutler, M; Cameron, S; Chapuy, B; Haase, D; Hupfeld, T; Koch, R; Larosee, P; Schrader, V; Truemper, L; Veltkamp, C; Wulf, GG | 1 |
| Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L | 1 |
| Costantini, A; Lasala, R; Rizzo, RC; Santoleri, F; Sorice, P | 1 |
| Antonescu, CR; Jain, S; Martz, J; Mosquera, JM; Popa, EC; Qin, L; Vahdat, LT | 1 |
| Gómez Casares, MT; León, LG | 1 |
| Alimena, G; Breccia, M | 5 |
| Tojo, A | 1 |
| Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ | 1 |
| Chumley, P; Fatima, H; Jaimes, EA; Lyndon, W; Wallace, E | 1 |
| Raanani, P | 1 |
| Hino, M; Koh, H; Koh, KR; Kosaka, S; Matsumoto, K; Morita, K; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M | 1 |
| Keam, SJ; Keating, GM; Lyseng-Williamson, KA; McCormack, PL | 1 |
| Irvine, E; Williams, C | 1 |
| Carrascosa, R; Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Steegmann, JL | 1 |
| Bell, J; Butt, NM; Clark, RE; De Soysa, L; Francis, S; Kaleel-Rahman, M; Knight, K; Lane, S; Lee, E; Lucas, C; O'Brien, D; Sadik, W; Salim, R; Seale, JR; Wang, L; Watmough, S | 1 |
| Borthakur, G; Cardenas-Turanzas, M; Cortes, J; Jabbour, E; Jain, P; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintás-Cardama, A; Ravandi, F; Romo, CG; Verstovsek, S | 1 |
| Mauro, MJ | 4 |
| Jiang, J; Lang, LW; Liu, F; Lu, HJ; Wang, JM; Wang, SC | 1 |
| Kataoka, T; Kayukawa, S; Kusumoto, S; Narita, T; Yoshida, T | 1 |
| Chu, E; Kim, EJ; Loren, A; Rook, A; Rosenbach, M; Samimi, S; Seykora, J; Vittorio, C | 1 |
| Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Gentile, M; Guido, M; Lucia, E; Mazzone, C; Morabito, F; Recchia, AG; Vigna, E | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Pregno, P; Riccomagno, P | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL | 1 |
| Ge, Z; Hong, M; Li, JY; Pan, LQ; Qian, SX; Song, P; Tian, T; Yu, H; Zhang, SJ; Zhu, Y | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Betkier-Lipińska, K; Cwetsch, A; Góra-Tybor, J; Ryczek, R | 1 |
| Klamová, H | 1 |
| Altavilla, G; Arrigo, C; Di Mirto, C; Mondello, P; Pitini, V | 1 |
| Hochhaus, A; Kantarjian, H | 1 |
| Saglio, G; Savona, MR | 1 |
| Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C | 1 |
| Abruzzese, E; Breccia, M; Latagliata, R | 1 |
| Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V | 1 |
| Miura, M; Takahashi, N | 1 |
| Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G | 1 |
| Chirovsky, DR; Davis, CC; Goren, A; Gupta, S; Hirji, I; Moadel, AB; Olavarria, E; Victor, TW | 1 |
| Ayyagari, R; Chen, L; Reichmann, WM; Signorovitch, J; Wu, EQ | 1 |
| Álvarez Álvarez, CM; Buchelli Ramirez, HL; Casan Clarà, P; García Clemente, MM; Rodríguez Reguero, JJ | 1 |
| Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D | 1 |
| Berger, F; Chassagne-Clément, C; Giraudier, S; Legros, L; Mollica, L; Niault, M; Nicolini, FE; Rea, D; Rousselot, P; Roux, C; Tigaud, I; Tulliez, M; Turhan, A | 1 |
| Giannouli, A; Hatzitolios, AI; Kaiafa, G; Kakaletsis, N; Papadopoulos, N; Perifanis, V; Savopoulos, C; Zisekas, S | 1 |
| Paydas, S | 1 |
| Kameoka, Y; Kume, M; Nagao, T; Noguchi, S; Ohyagi, H; Sawada, K; Shinohara, Y; Takahashi, N | 1 |
| Ando, T; Kimura, S; Kojima, K | 1 |
| Dehesa, L; Kerdel, F; Nuno-Gonzalez, A; Ricotti, C | 1 |
| Duek, A; Grisouard, J; Hao-Shen, H; Jeandidier, E; Karow, A; Looser, R; Lundberg, P; Ojeda-Uribe, M; Skoda, RC | 1 |
| Atanackovic, D; Goekkurt, E; Harbaum, L; Marx, A; Schafhausen, P | 1 |
| Beamish, M; Grabek, J; Mohamed, M | 1 |
| Arai, H; Handa, T; Iso, H; Mitani, K; Nagasawa, F; Nakamura, Y; Sasaki, K; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Baccarani, M; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; Kim, DW; Mayer, J; Mohamed, H; Pavlovsky, C; Saglio, G; Shah, NP; Steegmann, JL; Wildgust, M | 1 |
| Hughes, T; White, D | 1 |
| Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S | 1 |
| Brahmanday, GR; Chisti, MM; Khachani, A; Klamerus, J | 1 |
| Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A | 1 |
| Li, JY; Qiu, ZY; Xu, W | 1 |
| Asmussen, J; Burlingame, A; Craik, CS; Jun, YW; Lasater, EA; Oses-Prieto, J; Shah, NP; Tajon, C; Taylor, BS | 1 |
| Iijima, K; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Mori, T; Okita, H; Osumi, T; Saito, M; Shimizu, T; Tomita, O | 1 |
| Inokuchi, K; Nakayama, K | 1 |
| Irie, T; Izumiyama, K; Kato, T; Meguro, T; Mori, A; Morioka, M; Musashi, M; Saga, A; Saito, M; Tanaka, M; Tanino, M | 1 |
| Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS | 1 |
| Brümmendorf, TH; Cortes, JE; Cunningham, M; Guilhot, F; Healey, D; Hochhaus, A; Kantarjian, HM; le Coutre, P; Mohamed, H; Rousselot, P; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Brea, EJ; Dao, T; Dubrovsky, L; Liu, C; O'Reilly, RJ; Pankov, D; Scheinberg, DA; Scott, A; Yan, S | 1 |
| Arai, T; Imataki, O; Matsuoka, A; Uemura, M; Yamaoka, G | 1 |
| Hochhaus, A; Lindauer, M | 2 |
| Benjamini, O; Burger, J; Champlin, R; Cortes, J; Dumlao, TL; Faderl, S; Garcia-Manero, G; Garris, R; Jabbour, E; Jorgensen, J; Kantarjian, H; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, D | 1 |
| Anwer, F; Vincelette, ND; Yun, S | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Elverdi, T; Eskazan, AE; Eyice, D; Ferhanoglu, B; Kurt, EA; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Soysal, T; Tuzuner, N; Yalniz, FF | 1 |
| Almeida, DR; Chin, EK; Grant, LW | 1 |
| Baturin, D; Christians, U; DeGregori, J; Gardner, LA; Gore, L; Gregory, MA; Klawitter, J; Pollyea, DA; Porter, CC; Takebe, N; Zaberezhnyy, V | 1 |
| Chang, H; Chou, WC; Hung, YS | 1 |
| Bhatia, R; Chen, W; Chu, S; Liu, Z; Roth, M; Wang, J; Wang, Z; Wu, X; Yuan, H; Yuan, YC | 1 |
| Handa, H; Ishizaki, T; Koiso, H; Mitsui, T; Murakami, H; Nojima, Y; Ogawa, Y; Saitoh, T; Sekigami, T; Takizawa, M; Tsukamoto, N; Yokohama, A | 1 |
| Chen, Y; Li, L; Lu, F; Zhang, J; Zheng, T; Zhou, S; Zhu, JJ | 1 |
| Hori, S; Yamamoto, K | 1 |
| Liu, B; Mi, Y; Wang, J; Wang, Y | 1 |
| Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M | 1 |
| Fialho, A; Sami, MB; Yousaf, F | 1 |
| Ahmad, S; Anderson, DJ; Arpin, CC; Baron, R; Deininger, MW; Eiring, AM; Engar, AJ; Gunning, PT; Heaton, WL; Khorashad, JS; Kraft, IL; Mason, CC; Moriggl, R; O'Hare, T; Page, BDG; Pomicter, AD; Resetca, D; Reynolds, KR; Senina, A; Tantravahi, SK; Todic, A; Vellore, NA; Wilson, DJ; Zabriskie, MS; Zhang, TY | 1 |
| Cho, EH; Chung, Y; Eom, HS; Kong, SY; Lee, H; Park, S; Shim, H | 1 |
| Fukushima, N; Hayashi, S; Kimura, S; Kojima, K; Sueoka, E; Tomimasu, R; Yoshimura, M | 1 |
| Branford, S; Cortes, J; Gonen, M; Hughes, T; Michor, F; Olshen, A; Quintás-Cardama, A; Tang, M | 1 |
| Chen, M; Jiang, X; Lin, H; Lorenzi, MV; Rothe, K; Woolfson, A | 1 |
| Darkow, T; Landsman-Blumberg, P; McMorrow, D; Mullins, CD; Smith, D; Trivedi, D | 1 |
| Matsumura, I | 2 |
| Takahashi, N | 1 |
| Gambacorti-Passerini, C; Piazza, R | 1 |
| Doki, Y; Ezoe, S; Hata, T; Kudo, T; Matsumoto, K; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Takemasa, I; Uemura, M; Yamamoto, H | 1 |
| Lin, D; Liu, B; Lyu, R; Mi, Y; Wang, J; Zhou, C | 1 |
| Blalock, SJ; Earnshaw, SR; Fang, G; Happe, LE; Richards, KL; Walko, CM; Ward, MA | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Whiteley, J | 1 |
| Babiker, HM; Proytcheva, M | 1 |
| Fujisawa, S; Hatta, Y; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Dong, C; Huang, X; Ren, J; Ruan, L; Shao, C; Su, D; Wang, J | 1 |
| Chiba, S; Fujisawa, S; Igarashi, T; Inokuchi, K; Iriyama, N; Kawakami, K; Kouzai, Y; Kumagai, T; Morita, S; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Taguchi, J; Takezako, N; Wakita, H; Yano, S; Yoshida, C | 1 |
| Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B | 1 |
| Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT | 1 |
| Bamdad, M; Berger, J; Berger, MG; Boiret-Dupré, N; Bourgne, C; Briançon, A; Guerci, A; Hermet, E; Janel, A; Lioret, F; Rapatel, C; Tournilhac, O | 1 |
| Audemard, A; Bergot, E; Chantepie, S; de la Gastine, B; Gac, AC; Reman, O; Verger, H | 1 |
| Clark, RE; Giannoudis, A; Harris, RJ; Lucas, CM | 1 |
| Wolf, D | 1 |
| Collassanti, MDS; Covas, DT; de Castro, FA; de Oliveira, GLV; de Souza, AM; Ferreira, AF; Hamerschlak, N; Kashima, S; Tognon, R; Zanichelli, MA | 1 |
| Lee, CS; Liu, TC; Wang, HC | 1 |
| Eigendorff, E; Ernst, T; Hochhaus, A; La Rosée, P | 1 |
| Ar, MC; Eskazan, AE; Hatemi, İ; Öngören Aydın, S; Soysal, T | 1 |
| Cabezón, M; Cortés, M; Feliu, E; Grau, J; Marcé, S; Millá, F; Zamora, L | 1 |
| Amin, K; Dincer, HE; Podgaetz, E; Randall, N; Ustun, C | 1 |
| Albano, F; Anelli, L; Brunetti, C; Casieri, P; Cellamare, A; Coccaro, N; Cumbo, C; Delia, M; Impera, L; Minervini, A; Minervini, CF; Orsini, P; Specchia, G; Tota, G; Zagaria, A | 1 |
| Lavie, M; Rottenstreich, A; Rottenstreich, M | 1 |
| Fujii, S; Miura, I; Tanaka, H | 1 |
| Chen, L; Wu, EQ | 1 |
| Ross, DM | 1 |
| Landsman-Blumberg, PB | 1 |
| Choi, YG; Kim, JA; Lee, J; Nam, YJ; Yim, E | 1 |
| Cai, ZP; Chai, XX; Fu, YJ; Xiong, YZ; Yang, MT; Zhou, Y | 1 |
| Abbe, P; Benhida, R; Cavazza, E; Cerezo, M; Jaune, E; Millet, A; Plaisant, M; Rocchi, S; Ronco, C | 1 |
| Fenton, B; Quick, DP; Shakespeare, A; Shanshal, M; Thirumala, S | 1 |
| Valent, P | 3 |
| Dang, P; Eadie, L; Frede, A; Hewett, D; Hiwase, DK; Hughes, TP; Kumar, S; Melo, J; Saunders, V; To, LB; White, DL; Zrim, S | 1 |
| Akin, C; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Manshouri, T; O'Brien, S; Pardanani, A; Tefferi, A; Thomas, D; Verstovsek, S | 1 |
| Tuma, RS | 2 |
| Deininger, MW | 1 |
| Arnold, R; Guilhot, F; Koren-Michowitz, M; le Coutre, P; Leiba, M; Martineau, G; Nagler, A; Renaud, M; Ribakovski, E; Schleuning, M; Shimoni, A | 1 |
| Bonvin, A; Cotte, L; Descotes, J; Mesnil, A; Michallet, M; Nicolini, FE; Vial, T | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Lucas, CM; Pirmohamed, M | 1 |
| Wong, SF | 2 |
| Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C | 1 |
| Bengoufa, D; Bergeron, A; Dombret, H; Fieschi, C; Oksenhendler, E; Rea, D | 1 |
| Blackwood-Chirchir, A; Dai, G; Pfister, M; Roy, A | 1 |
| Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N | 1 |
| Wang, ES; Wetzler, M; Zeidan, A | 1 |
| Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F | 1 |
| Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Kubuki, Y | 1 |
| Hohl, RJ; Holstein, SA; Stokes, JB | 1 |
| Bewry, NN; Boulware, D; Emmons, MF; Hazlehurst, LA; Nair, RR; Pinilla-Ibarz, J | 1 |
| Alnadaf, T; Buchdunger, E; Day, E; Jarai, G; Manley, PW; Spiegel, K; Walker, C; Waters, B | 1 |
| Ingley, E; Klinken, SP; Lucet, IS; Rossjohn, J; Williams, NK | 1 |
| Flaim, B; Rasheed, W; Seymour, JF | 1 |
| Deliliers, GL; Ghidoni, R; Onida, F; Radaelli, F; Ricci, C; Saporiti, G; Servida, F; Todoerti, K | 1 |
| Del Cañizo, MC; González, M; Gonzalez, T; Lopez-Jimenez, J; Sanchez-Guijo, FM; Santamaría, C | 1 |
| Bhatia, R; Chu, S; Copland, M; Holyoake, TL; Jove, R; Konig, H | 1 |
| Belanger, C; Belloc, F; Etienne, G; Hayette, S; Lagarde, V; Leroy, C; Mahon, FX; Manley, PW; Nicolini, F; Pasquet, JM; Roche, S; Turcq, B | 1 |
| Balbas, M; Bleickardt, E; Kasap, C; Nicaise, C; Nicoll, JM; Sawyers, CL; Shah, NP; Weier, C | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Chang, H; Jung, CW; Kamel-Reid, S; Kim, DH; Kim, HJ; Lee, JJ; Lipton, JH; Sutherland, R | 1 |
| Chuah, C; Melo, JV | 1 |
| Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R | 1 |
| Gora-Tybor, J; Robak, T | 1 |
| Cervantes, F | 1 |
| Bik To, L; Dewar, AL; Farrugia, AN; Fitter, S; Hughes, TP; Vandyke, K; Zannettino, AC | 1 |
| Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W | 1 |
| Müller, BA | 1 |
| Cortes, JE; Jabbour, E; Kantarjian, HM | 1 |
| Kantarjian, H | 1 |
| Cortes, JE; Guilhot, F; Hughes, TP; Khoury, HJ; Kim, DW | 1 |
| Brizard, F; Chomel, JC; Cividin, M; Guilhot, F; Méchinaud, F; Millot, F | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carotti, A; Santopietro, M; Stefanizzi, C | 1 |
| Hantschel, O; Kuriyan, J; Superti-Furga, G; Winger, JA | 1 |
| Cortés, JE; Jabbour, E; Kantarjian, H | 2 |
| Cortés, JE; Kantarjian, H; Quintás-Cardama, A | 1 |
| Bixby, DL; Talpaz, M | 1 |
| Cortes, J; Fava, C; Kantarjian, H; Verma, D | 1 |
| Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Alimena, G; Breccia, M; Capria, S; De Propris, MS; Diverio, D; Grammatico, S; Latagliata, R; Matturro, A; Meloni, G | 1 |
| Arstila, TP; Dybedal, I; Ekblom, M; Epling-Burnette, PK; Guilhot, F; Hjorth-Hansen, H; Höglund, M; Kovanen, P; Laurinolli, T; Liesveld, J; Mustjoki, S; Paquette, R; Pinilla-Ibarz, J; Porkka, K; Rauhala, A; Shah, N; Simonsson, B; Sinisalo, M; Steegmann, JL; Stenke, L | 1 |
| Cortes, JE; Kantarjian, H; Pavlovsky, C | 1 |
| Tyler, T | 1 |
| McFarland, KL; Wetzstein, GA | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 4 |
| Giles, FJ | 2 |
| Bellodi, C; Calabretta, B; Dinsdale, D; Donato, N; Dyer, MJ; Galavotti, S; Hamilton, A; Helgason, GV; Holyoake, T; Hunter, A; Lidonnici, MR; Nicotera, P; Ronchetti, M; Salomoni, P; Selmi, T; Soliera, AR; Tirrò, E; Van Etten, RA; Vigneri, P; Yacobi, R; Young, KW | 1 |
| Akin, RS; Cobos, E; Smith, J; Sun, A | 1 |
| Alimena, G; Breccia, M; Cannella, L; Napoleone, L; Santopietro, M; Stefanizzi, C | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Bilban, M; Burkard, TR; Colinge, J; Gstoettenbauer, A; Hantschel, O; Kaupe, I; Superti-Furga, G; Valent, P | 1 |
| Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Scuffham, PA; Taylor, MJ | 1 |
| Cortes, J; Han, X; Kantarjian, H; Quintás-Cardama, A | 1 |
| Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M | 1 |
| Arcamone, M; Di Francia, R; Frigeri, F; Luciano, L; Pane, F; Pinto, A | 1 |
| Agrawal, S; Bradley-Garelik, MB; Caguioa, PB; Dai, D; Goh, YT; Hsiao, HH; Jootar, S; Kim, D; Kim, DW; Kim, WS; Mukhopadhyay, J; Roy, A; Saikia, T | 1 |
| Ambrosetti, A; Nichele, I; Pizzolo, G; Tecchio, C; Todeschini, G | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V | 1 |
| Storey, S | 1 |
| Abruzzese, E; Apperley, JF; Bullorsky, EO; Cortes, JE; de Souza, CA; Erben, P; Heim, D; Hochhaus, A; Hughes, TP; Khoury, HJ; Kim, DW; Kim, HJ; Larson, RA; Lipton, JH; Roboz, GJ; Rosti, G; Roy, L; Sillaber, C; Stone, RM; Van Tornout, J | 1 |
| Bryant, G | 1 |
| Buchanan, S; Galinsky, I | 1 |
| Awais, A; Borthakur, G; Cortes, J; De Souza Santos, FP; Faderl, S; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Damaj, G; Garidi, R; Marolleau, JP; Parcelier, A; Roszkiewicz, F; Royer, B; Vaida, I | 1 |
| Dazzi, F; Garland, P; Marin, D | 1 |
| Borthakur, G; Burger, JA; Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; Koller, C; O'Brien, S; Tam, C; Wierda, WG | 1 |
| Cetkovský, P; Klamová, H; Machová Poláková, K; Marková, M; Moravcová, J; Sisková, M | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S | 1 |
| Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Müller, MC; Niederwieser, D; Pelz-Ackermann, O; Pfirrmann, M; Porkka, K | 1 |
| Cortes, J; Fava, C | 1 |
| Jabbour, E; Soverini, S | 1 |
| Kimura, S | 4 |
| Daub, H; Mann, M; Olsen, JV; Pan, C | 1 |
| Balachandran, H; Carayol, N; Dumka, D; Lumby, C; Parmar, S; Platanias, LC; Puri, P; Schuster, K; Terada, LS; Verma, AK | 1 |
| Cortes, J; Quintás-Cardama, A | 3 |
| Cooper, JM; Copland, M; Faley, SL; Kolch, W; Seale, KT; Wikswo, JP; Wlodkowic, D | 1 |
| Adrian, LT; Deininger, MW; Druker, BJ; Eide, CA; Lange, T; O'Hare, T; Snead, JL | 1 |
| Abakumov, EM; Chelysheva, EIu; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Khoroshko, ND; Kuznetsov, SV; Misiurin, AV; Sokolova, MA; Stakhina, OV; Turkina, AG; Vinogradova, OIu; Vorontsova, AV | 1 |
| Botta, M; Bruno, O; Radi, M; Schenone, S | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Baumgartner, C; Bennett, K; Böhm, A; Herndlhofer, S; Herrmann, H; Jäger, U; Rix, U; Sillaber, C; Superti-Furga, G; Tschachler, E; Valent, P | 1 |
| Amano, M; Fujii, Y; Seriu, T | 1 |
| Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Branford, S; Cortes, JE; Druker, BJ; Erben, P; Hochhaus, A; Hughes, TP; Kim, DW; Mukhopadhyay, J; Müller, MC; Pasquini, R; Ploughman, L; Radich, JP | 1 |
| Bauer, S; Romvari, E | 1 |
| Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P | 1 |
| Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF | 1 |
| Divoka, M; Divoky, V; Faber, E; Indrak, K; Jarosova, M; Mojzikova, R; Plachy, R; Rozmanova, S; Stastny, M | 1 |
| Goldstein, JL | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R | 1 |
| Doelken, P; Goldblatt, M; Gurung, P; Huggins, JT; Sahn, SA | 1 |
| Berretta, S; Buscarino, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; Massimino, M; Messina, A; Pennisi, MS; Restuccia, N; Stagno, F; Stella, S; Tibullo, D; Tirrò, E; Vigneri, P | 1 |
| Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP | 1 |
| Branford, S; Hughes, TP; Melo, JV | 1 |
| Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Pane, F; Radich, J; Saglio, G; Silver, RT; Simonsson, B | 1 |
| Gorospe, G; Masiello, D; Yang, AS | 1 |
| Matsunaga, T | 1 |
| Guilhot, F; Roy, L | 1 |
| Marin, D; Pavlů, J | 1 |
| Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T | 1 |
| Kambhampati, S | 1 |
| Hiwase, DK; Hughes, TP; Melo, JV; Saunders, V; White, D; Zrim, S | 1 |
| Ravandi, F; Santos, FP | 1 |
| Azam, M; Clackson, T; Daley, GQ; Dalgarno, D; Einhorn, W; Huang, WS; Powers, JT; Sawyer, TK; Shakespeare, WC; Zhu, X | 1 |
| Attar, EC; DeAngelo, DJ | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Kiselev, Y; Mikkola, I | 1 |
| Gotoh, M; Kiguchi, T; Kimura, Y; Kitahara, T; Ohyashiki, K; Tauchi, T; Yoshizawa, S | 1 |
| Baird, K; Bishop, MR; Cowen, EW; Pavletic, SZ; Pulanic, D | 1 |
| Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P | 1 |
| D'Andrea, RJ; Frede, AK; Guthridge, MA; Hiwase, DK; Hughes, TP; Kumar, S; Lopez, AF; Melo, JV; Powell, JA; Saunders, VA; To, LB; White, DL; Zrim, SA | 1 |
| Ashihara, E; Fujiyama, Y; Imoto, M; Kawatani, M; Kimura, S; Kuroda, J; Maekawa, T; Nagao, R; Nakahata, T; Osada, H; Takeuchi, M; Tanaka, R; Tsuruo, T; Umezawa, K; Yasui, E; Yokota, A | 1 |
| Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A | 1 |
| Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T | 1 |
| Condorelli, F; Genazzani, AA | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Martinelli, G; Palandri, F; Rosti, G | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Chen, J; Shen, J; Zheng, Z; Zhou, Y | 1 |
| Kasada, A; Munemoto, S; Murata, R; Ueda, M; Yamaguchi, M | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Brixey, AG; Light, RW | 1 |
| Hatsumi, N; Hoshino, T; Miyawaki, K; Miyawaki, S; Sakura, T; Tahara, K; Takada, S | 1 |
| Han, L; Mulder, A; Schuringa, JJ; Vellenga, E | 1 |
| Akiyama, H; Fukuda, S; Kamata, N; Nagata, Y; Ohashi, K; Sakamaki, H | 1 |
| Duesberg, P; Fabarius, A; Giehl, M; Haferlach, C; Hochhaus, A; Hofheinz, R; Hofmann, WK; Leitner, A; Seifarth, W | 1 |
| Ekblom, M; Juvonen, V; Kairisto, V; Kreutzman, A; Mustjoki, S; Porkka, K; Seggewiss, R; Stenke, L | 1 |
| Schiffer, CA; Zonder, JA | 1 |
| Alvarado, Y; Cortes, J; Giles, FJ; Swords, R | 1 |
| Brezinova, J; Cetkovsky, P; Cmunt, E; Dvorakova, D; Faber, E; Indrak, K; Jarosova, M; Klamova, H; Machova-Polakova, K; Markova, M; Mayer, J; Michalova, K; Moravcova, J; Novakova, L; Oltova, A; Voglova, J; Zackova, D | 1 |
| Ballestrero, A; Cagnetta, A; Cea, M; Cirmena, G; Colombo, N; Fugazza, G; Garuti, A; Gobbi, M; Grasso, R; Moran, E; Nencioni, A; Palermo, C; Patrone, F; Rocco, I | 1 |
| Billström, R; Ekblom, M; Fioretos, T; Larsson, N; Lassen, C; Lilljebjörn, H; Richter, J | 1 |
| Bazarbachi, A; Mahfouz, RA; Otrock, ZK; Oweini, H | 1 |
| Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D | 1 |
| Albano, F; Anelli, L; Casieri, P; Coccaro, N; Liso, V; Rocchi, M; Rossi, AR; Specchia, G; Vicari, L; Zagaria, A | 1 |
| Baccarani, M; Saglio, G | 1 |
| Deininger, MW; Traer, E | 1 |
| Cortés, JE; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Cortes, J; Fava, C; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Santos, FP; Shan, J; Thomas, D; Wierda, W | 1 |
| Bradley-Garelik, MB; Cortes, J; Dombret, H; Erben, P; Goh, YT; Hochhaus, A; Maloisel, F; Masszi, T; Paquette, R; Pasquini, R; Saglio, G; Zhu, C | 1 |
| Graves, LM; Lawrence, DS; Martin, TD; Toutchkine, A; Wang, Q; Zimmerman, EI | 1 |
| Alvarez-Calderon, F; Degregori, J; Druker, BJ; Eide, CA; Gregory, MA; Neviani, P; O'Hare, T; Perrotti, D; Phang, TL; Williams, RT; Zaberezhnyy, V | 1 |
| Ghatnekar, O; Hjalte, F; Taylor, M | 1 |
| Ames, MB; Fenske, TS; Kroll, T; Pruett, JA | 1 |
| Barbany, G; Engdahl, I; Hermansson, M; Höglund, M; Lundán, T; Ohm, AC; Olsson-Strömberg, U; Porkka, K; Simonsson, B | 1 |
| Mustjoki, S; Porkka, K; Rohon, P | 1 |
| Chabane, K; Cony-Makhoul, P; Hayette, S; Magaud, JP; Maguer-Satta, V; Michallat, E; Michallet, M; Nicolini, FE; Salesse, S | 1 |
| Joseph, A; Kingham, BF; Martin, SE; Sausen, M | 1 |
| Smith, BD; Stein, B | 1 |
| Aldred, VL; Bendit, I; Cavalcante, M; de Paula, HM; Dorlhiac-Llacer, PE; Nardinelli, L; Seguro, F; Serpa, M; Steinbaum, D; Xavier, F | 1 |
| Chen, Y | 1 |
| Chen, X; Feng, Z; Jin, J; Li, X; Liu, H; Yuan, X; Zhang, H; Zhang, Y | 1 |
| Birge, RB; Matsuda, M; Tunceroglu, A | 1 |
| Hibi, T; Iwao, Y; Kato, J; Mori, T; Okamoto, S; Ono, Y; Yajima, T; Yamane, A | 1 |
| Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Ibrahim, AR; Khorashad, JS; Marin, D; Milojkovic, D; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Deininger, M; Hochhaus, A; Jabbour, E | 1 |
| Shayani, S | 1 |
| Breccia, M | 1 |
| Schiffer, CA; Valent, JN | 1 |
| Cortes, J; Mauro, MJ; Pinilla-Ibarz, J | 1 |
| Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J | 1 |
| Hassan, AQ; Sharma, SV; Warmuth, M | 1 |
| Herndlhofer, S; Krauth, MT; Mitterbauer-Hohendanner, G; Schlögl, E; Schmook, MT; Valent, P | 1 |
| Alimena, G; Breccia, M; Capria, S; Foà, R; Iori, AP; Meloni, G | 1 |
| Bencivenga, D; Borriello, A; Caldarelli, I; Cucciolla, V; Danise, P; Della Ragione, F; Oliva, A; Perrotta, S; Ronzoni, L; Usala, E | 1 |
| Bollu, VK; Griffin, JD; Guerin, A; Guo, A; Wu, EQ; Yu, AP | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Aota, Y; Gotoh, A; Sakurai, M; Takagi, Y | 1 |
| Clackson, T; Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T | 1 |
| Etienne, G; Huguet, F | 1 |
| Liu, D; Rafiyath, S; Wei, G | 1 |
| Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; Leitner, A; Lorentz, C; Müller, MC; Schenk, T; Schwindel, U | 1 |
| Cortés, JE; Holyoake, T; Kantarjian, H; Ranganathan, A; Saglio, G | 1 |
| Han, K; Kim, M; Kim, Y; Lee, SA; Lim, J | 1 |
| Hamšíková, E; Humlová, Z; Janatková, I; Klamová, H; Králíková, P; Malíčková, K; Roth, Z; Sterzl, I; Vonka, V | 1 |
| Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I | 1 |
| Cross, NC; Ernst, T; Hochhaus, A; La Rosée, P; Müller, MC | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Okimoto, RA; Van Etten, RA | 1 |
| Burchert, A; Neubauer, A | 1 |
| Adamson, PC; Agrawal, S; Aplenc, R; Balis, FM; Blaney, SM; Ingle, AM; Shusterman, S; Strauss, LC; Sun, J; Wright, JJ | 1 |
| Chen, Y; Li, D; Li, S; Peng, C | 1 |
| Hobernicht, SL; Hunger, SP; Schweiger, B; Wang, M; Zeitler, P | 1 |
| Baccarani, M; Cortes, JE; Jabbour, E; Kantarjian, HM; Saglio, G | 1 |
| Quintás-Cardama, A; Santos, FP | 1 |
| Bouvresse, S; Clérici, T; de Masson, A; Mahé, E; Saïag, P | 1 |
| Harnicar, S | 1 |
| Aydin, Y; Eskazan, AE; Ferhanoglu, B; Gulturk, E; Ongoren, S; Soysal, T | 1 |
| Branford, S; Prime, J | 1 |
| Griffiths, EA; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Jung, CW; Kim, DH; Kim, DY; Kim, HJ; Kim, IH; Kwak, JY; Lee, KH; Lee, SJ; Park, S; Sohn, SK | 1 |
| Gaultney, JG; Janssen, JJ; Redekop, WK; Sanhueza, E; Uyl-de Groot, CA | 1 |
| Silver, RT | 1 |
| Breccia, M; Isidori, A; Montefusco, E; Morra, E; Santini, V; Visani, G | 1 |
| Avcu, F; Baran, Y; Gencer, EB; Ural, AU | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Federico, V; Loglisci, G; Loglisci, MG; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Amrein, PC | 1 |
| Bueso-Ramos, C; Chen, SS; Cortes, JE; Esmaeli, B; Katz, RL; Khanna, A; Manning, JT; Miranda, RN; Shinder, R; Verstovsek, S; Vigil, CE; Wang, SA; You, MJ | 1 |
| Craddock, C; Novitzky-Basso, I | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Oyekunle, AA; Rosti, G; Soverini, S | 1 |
| Drummond, M; Gallipoli, P; Holyoake, T; Irvine, D; Shepherd, P | 1 |
| Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Shan, J; Verstovsek, S | 1 |
| Betts, KA; Bollu, VK; DeAngelo, DJ; Guo, A; Kantor, E; Parikh, K; Signorovitch, JE; Wei, LJ; Williams, D; Wu, EQ | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K | 1 |
| Baumann, HJ; Bokemeyer, C; Brümmendorf, TH; Hennigs, JK; Honecker, F; Keller, G; Klose, H; Kluge, S | 1 |
| Erbilgin, Y; Eskazan, AE; Ferhanoglu, B; Ozbek, U; Soysal, T | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S | 1 |
| Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rodrigues, AS; Rueff, J; Tavares, P | 1 |
| Cortes, J; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Hiwase, DK; White, DL; Yeung, DT | 1 |
| Guo, L; He, L; Li, J; Xu, G; Yu, S | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Pane, F; Pregno, P; Rege-Cambrin, G; Rosti, G; Russo Rossi, A; Santini, V; Sica, S; Specchia, G; Stagno, F; Vigneri, P | 1 |
| Abdool, A; Bruey, JM; Yeh, CH | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Binotto, G; Breccia, M; Castagnetti, F; Cavazzini, F; Crisà, E; Fava, C; Feo, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Occhini, U; Pregno, P; Rossi, AR; Rosti, G; Santini, V; Sorà, F; Stagno, F; Tiribelli, M; Ulisciani, S; Vigneri, P | 1 |
| Radich, JP | 1 |
| Hughes, TP; Moore, S; Parker, WT; Prime, JA; Schafranek, L; Tang, C; Watkins, DB; White, DL | 1 |
| Dumitrescu, D; Erdmann, E; Gerhardt, F; Rosenkranz, S; Seck, C; ten Freyhaus, H | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Smith, BD; Stein, BL | 1 |
| Ikegame, K; Kaida, K; Kato, R; Nakata, J; Ogawa, H; Okada, M; Satake, A; Tamaki, H; Yoshihara, S | 1 |
| Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Engh, RA; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Porkka, K | 1 |
| Ohnishi, K | 2 |
| Bartley, PA; Goyne, J; Grigg, AP; Morley, AA; Ross, DM; Seymour, JF | 1 |
| Dinh-Xuan, AT; Humbert, M; Simonneau, G | 1 |
| Bagadi, S; Das, B; Pany, A; Saikia, T | 1 |
| Ghio, S; Orlandi, EM; Pazzano, AS; Rocca, B | 1 |
| Cho, BS; Goh, HG; Kim, D; Kim, DW; Kim, SH | 1 |
| Keam, SJ; McCormack, PL | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
| Branford, S; Ho, M; Hughes, TP; Irwin, DL; Lawrence, RM; Parker, WT; Scott, HS | 1 |
| Chang, VY; Eckardt, MA; Federman, N; Rao, NP | 1 |
| Cornelison, AM; Jabbour, E; Koller, C; Welch, MA | 1 |
| Ariaudo, A; Baietto, L; Cusato, J; D'Avolio, A; De Francia, S; Di Carlo, F; Di Perri, G; Fava, C; Saglio, G; Simiele, M | 1 |
| Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O | 1 |
| Krusch, M; Salih, HR | 1 |
| Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T | 1 |
| Bendit, I; de Barros Ferreira, P; Dorlhiac-Llacer, PE; Martins, TF; Nardinelli, L; Sanabani, SS; Seguro, F; Serpa, M | 1 |
| Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Miura, M; Niioka, T; Sawada, K; Takahashi, N | 1 |
| Kalaycio, M; Tiu, R | 1 |
| Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU | 1 |
| Aoki, J; Hirashima, Y; Kakihana, K; Kobayashi, T; Ohashi, K; Sakamaki, H | 1 |
| Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Balci, TB; Karakus, S; Ozdogu, H; Sahin, FI | 1 |
| Allan, EK; Bhatia, R; Brunton, VG; Hamilton, A; Helgason, GV; Holyoake, TL; Koschmieder, S; Müller-Tidow, C; Myssina, S; Nicolini, FE; Schemionek, M; Zhang, B | 1 |
| Alessandro, R; De Leo, G; Flugy, A; Garfield, SH; Kohn, EC; Mineo, M; Taverna, S | 1 |
| Branford, S; Ho, M; Hughes, TP; Parker, WT; Scott, HS | 1 |
| Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Katayama, T; Koh, H; Nakamae, H; Nakamae, M; Nakane, T; Nakao, Y; Terada, Y | 1 |
| Beltrami, G; Carella, A; Carella, AM; Catania, G; Pica, G | 1 |
| Erba, HP; Pham, DC; Tai, S; Vu, H; Zaiden, R | 1 |
| Coluccia, AM; De Leo, S; de Luca, E; De Matteis, S; Di Renzo, N; Dini, L; Maffia, M; Palamà, I; Passerini, CG; Reddiconto, G; Toto, C | 1 |
| Ahmed, SI; Al-akhrass, F; Rallapalli, V; Rodriguez, GH; Safdar, A | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W | 1 |
| Dreosti, L; Jogessar, V; Louw, VJ; Moodley, D; Novitzky, N; Patel, M; Ruff, P; Schmidt, A; Willem, P | 1 |
| Abbott, BL | 1 |
| Auewarakul, CU; Thongnoppakhun, W; Wongboonma, W | 1 |
| Cooper, JM; Copland, M; Faley, S; Reboud, J | 1 |
| Fukushima, N; Ichinohe, T; Kimura, S | 1 |
| Goulden, S; Stevens, A; Sutcliffe, F | 1 |
| Andreoli, A; Anselem, O; Berveiller, P; Chapuis, N; Delezoide, AL; Mir, O; Sauvageon, H; Tsatsaris, V | 1 |
| Pfirrmann, M; Saussele, S | 1 |
| Wise, J | 1 |
| Chen, C; Ding, K; Jin, B; Pan, J; Shi, X; Sun, X; Wu, Y; Yeung, SC | 1 |
| Atallah, E; Haddad, RY; Torgerson, SR | 1 |
| Force, T | 1 |
| Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC | 1 |
| Boxer, SG; Levinson, NM | 1 |
| Di Raimondo, F; Stagno, F; Vigneri, P | 1 |
| Koskela, H; Koskenvesa, P; Mustjoki, S; Porkka, K | 1 |
| Jootar, S | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 1 |
| Giles, F; Gjertsen, B; Labar, B; Mahon, FX; Rosti, G; Swords, R; Turkina, A | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Katagiri, S; Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Hughes, TP; Leclercq, TM; Schafranek, L; White, DL | 1 |
| Kawakami, K; Matsunaga, T; Matsuoka, A; Miura, M; Niioka, T; Sawada, K; Takahashi, N | 1 |
| Chen, L; Wu, E | 1 |
| Alvarez, S; Blanco, R; Bretones, G; Caraballo, JM; Cigudosa, JC; Delgado, MD; Ferrándiz, N; García-Alegria, E; Gómez-Casares, MT; León, J; López-Jorge, CE; Martín-Perez, J; Sánchez-Bailón, P; Vaqué, JP | 1 |
| Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ | 1 |
| Nakashima, S; Tanaka, H; Usuda, M | 1 |
| Bayraktar, S; Escalón, MP; Morency, B | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Luciano, L; Martino, B; Musto, P; Pregno, P; Rosti, G; Russo Rossi, A; Sgherza, N; Specchia, G; Stagno, F; Tiribelli, M; Visani, G | 1 |
| Alimena, G; Annunziata, M; Breccia, M; Calistri, E; Capodanno, I; Castagnetti, F; Cavazzini, F; Crugnola, M; Fava, C; Ferrero, D; Gozzini, A; Gugliotta, G; Iurlo, A; Latagliata, R; Luciano, L; Musto, P; Stagno, F; Tiribelli, M; Vigneri, P; Visani, G | 1 |
| Fava, C; Rege-Cambrin, G; Saglio, G | 1 |
| Ali, S; Alsuliman, A; Apperley, JF; Clark, RE; Cooper, N; Foroni, L; Gabriel, IH; Gerrard, G; Gilleece, M; Goldman, JM; Hedgley, C; Khoder, A; Marin, D; Milojkovic, D; O'Brien, SG; Rezvani, K; Sergeant, R; Stringaris, K | 1 |
| Cayuela, JM; Ekblom, M; Greco, D; Guerci-Bresler, A; Hjorth-Hansen, H; Jaatinen, T; Kreutzman, A; Lipton, J; Mahon, FX; Melo, T; Mustjoki, S; Paquette, R; Partanen, J; Porkka, K; Richter, J; Rousselot, P; Seggewiss-Bernhardt, R; Stenke, L; Talbot, A; Vakkila, E | 1 |
| Dingermann, T; Marschalek, R; Zündorf, I | 1 |
| Airley, R | 1 |
| Auberger, P; Aumann, K; Braun, S; Brummer, T; Daly, RJ; Halbach, S; Laßmann, S; Pahl, HL; Penninger, JM; Schramek, D; Schwemmers, S; Waller, CF; Werner, M; Wöhrle, FU; Zeiser, R | 1 |
| Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL | 1 |
| Bahl, A; Gupta, R; Kumar, L; Raina, V; Sharma, A | 1 |
| Jabbour, E; Mathisen, MS; O'Brien, S | 1 |
| Hayashi, H; Katoh, H; Ohnishi, K; Sano, M; Saotome, M; Satoh, H; Urushida, T | 1 |
| Badura, S; Khateb, M; Mahajna, J; Metodieva, A; Mian, AA; Najajreh, Y; Ottmann, OG; Ruimi, N; Ruthardt, M | 1 |
| Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O | 1 |
| Bowles, DW; Green, K; Thienelt, CD | 1 |
| Dan, K; Inokuchi, K; Tamai, H; Yamaguchi, H | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Zacheo, I | 1 |
| Cross, M; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Müller, MC; Niederwieser, D; Pfirrmann, M | 1 |
| Hiwase, DK; Hughes, TP; Nievergall, E; Ross, DD; Saunders, VA; White, DL | 1 |
| Jabbour, E; Kantarjian, H | 1 |
| Furukawa, T; Iwabuchi, M; Narita, M; Sato, N; Sone, H; Takahashi, M; Uchiyama, T; Yamahira, A | 1 |
| Hirase, C; Matsumura, I | 1 |
| Anderson, R; Ciani, O; Cooper, C; Crathorne, L; Garside, R; Hoyle, M; Jones-Hughes, T; Osipenko, L; Pavey, T; Rudin, C; Ukoumunne, O; Venkatachalam, M | 1 |
| Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S | 1 |
| Dai, M; Meng, F; Wang, Q; Wei, Y; Xu, N; Yin, C; Zhou, HS | 1 |
| Marin, D | 2 |
| Auberger, P; Cassuto, JP; Cassuto, O; Dubois, A; Dufies, M; Ginet, C; Hamouda, A; Jacquel, A; Karsenti, JM; Legros, L; Lenain, P; Luciano, F; Puissant, A; Robert, G | 1 |
| Amitay-Laish, I; Berman, E; Busam, KJ; Drucker, AM; Lacouture, ME; Wu, S | 1 |
| Baxendale, IR; Deadman, BJ; Hopkin, MD; Ley, SV | 1 |
| Dolgin, E | 1 |
| Bellisola, G; Cinque, G; Gambacorti Passerini, C; Moratti, E; Redaelli, S; Silvestri, G; Sorio, C; Vezzalini, M; Wehbe, K | 1 |
| Barbany, G; Dybedal, I; Ehrencrona, H; Fioretos, T; Gedde-Dahl, T; Gjertsen, BT; Hernesniemi, S; Hjorth-Hansen, H; Hovland, R; Josefsen, D; Koskenvesa, P; Markevärn, B; Mustjoki, S; Olofsson, T; Olsson-Strömberg, U; Porkka, K; Rapakko, K; Richter, J; Simonsson, B; Stenke, L; Thunberg, S | 1 |
| Hu, JD; Huang, XJ; Jin, J; Li, JY; Liu, T; Meng, FY; Shen, ZX; Wang, JM; Wang, JX; Wu, DP | 1 |
| Simoneau, CA | 1 |
| Cetkovsky, P; Cmunt, E; Dusek, L; Dvorakova, D; Jurcek, T; Klamova, H; Machova Polakova, K; Mayer, J; Muzik, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Jabbour, EJ; Quintás-Cardama, A | 1 |
| Besra, SE; Bhattacharya, S; Das, M; Ghosh, P; Gomes, A; Majumdar, J; Mitra, S; Murmu, N; Sur, P; Vedasiromoni, JR | 1 |
| Travis, J | 1 |
| Chen, P; Lee, FY; Norris, D; Sawyers, CL; Shah, NP; Tran, C | 1 |
| Nelson, L | 1 |
| Emerson, SG; Gewirtz, AM; Kalota, A; Nakata, Y; Ptasznik, A | 1 |
| Doggrell, SA | 1 |
| Cowan-Jacob, SW; Deininger, MW; Druker, BJ; Heinrich, MC; Jia, T; Lee, FY; Manley, PW; Mestan, J; O'Hare, T; Stoffregen, EP; Walters, DK | 1 |
| Deininger, MW; Druker, BJ; Heinrich, MC; O'Hare, T; Sherbenou, DW; Stoffregen, EP; Walters, DK | 1 |
| D'Antonio, J | 1 |
| Shah, NP | 2 |
| Corbin, AS; Druker, BJ; O'Hare, T | 1 |
| Biggs, WH; Chao, LH; Kuriyan, J; Lockhart, DJ; Milanov, ZV; Patel, HK; Sawyers, CL; Seeliger, M; Shah, NP; Treiber, DK; Young, MA; Zarrinkar, PP | 1 |
| Hampton, T | 1 |
| Allan, EK; Baird, JW; Barow, M; Copland, M; Elrick, LJ; Hamilton, A; Holyoake, TL; Jordanides, N; Mountford, JC | 1 |
| Calabretta, B; Cattelani, S; Donato, NJ; Ferrari-Amorotti, G; Guerzoni, C; Iotti, G; Keeshan, K; Zattoni, M | 1 |
| Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M | 1 |
| Druker, BJ | 1 |
| Fricker, J | 2 |
| Chomel, JC; Guilhot, F; Martineau, G; Roy, L; Sorel, N; Turhan, AG | 1 |
| Kathula, SK | 1 |
| Chu, SC; Li, CC; Tang, JL | 1 |
| Cortes, J; Giles, F; Jones, D; Kantarjian, H; Nicaise, C; O'Brien, S; Quintas-Cardama, A; Talpaz, M | 1 |
| Grimley, J; Jabbour, E; Kantarjian, H; Kirkpatrick, P | 1 |
| Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K | 1 |
| Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R | 1 |
| Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 2 |
| Apperley, JF; Baccarani, M; Cervantes, F; Countouriotis, AM; Druker, BJ; Ezzeddine, R; Facon, T; Goldberg, SL; Hochhaus, A; Hughes, TP; Kantarjian, HM; Lipton, JH; Muller, MC; Niederwieser, D; Shah, NP; Silver, RT; Stone, RM | 1 |
| Blackwood-Chirchir, A; Camuso, A; Castaneda, S; Fager, K; Flefleh, C; Inigo, I; Kan, D; Kramer, R; Lee, FY; Luo, FR; McGlinchey, K; Smykla, R; Wen, ML; Yang, Z | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 2 |
| Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N | 1 |
| Chabane, K; Hayette, S; Magaud, JP; Michallet, M; Nicolini, FE; Tigaud, I | 1 |
| Dent, P; Grant, S; Harada, H; Nguyen, TK; Rahmani, M | 1 |
| Chen, XG; Liu, H | 1 |
| Czyz, M; Jakubowska, J | 1 |
| Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Maekawa, T | 1 |
| Baccarani, M; Castagnetti, F; Colarossi, S; Gnani, A; Martinelli, G; Paolini, S; Rondoni, M; Rosti, G; Soverini, S | 1 |
| Heaney, NB; Holyoake, TL | 1 |
| Aguilon, P; Charbonnier, A; Gisserot, O; Mozziconacci, MJ; Olschwang, S; Popovici, C; Rémy, V | 1 |
| Bhalla, K; Jove, R; Lee, FY; List, A; Nam, S; Smith, D; Vultur, A; Williams, A | 1 |
| Cannell, E | 1 |
| Ault, P | 1 |
| Ohyashiki, K; Tauchi, T | 1 |
| Chan, AS; Cheng, CH; Cheng, GY; Cheung, F; Chui, CH; Gambari, R; Kok, SH; Lai, PB; Lam, WS; Lau, FY; Tang, JC; Teo, IT; Wong, RS; Yu, MW | 1 |
| Abdelhalim, A; Barcos, M; Block, AW; Sait, SN; Starostik, P; Wang, ES; Wetzler, M | 1 |
| Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W | 1 |
| Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Kantarjian, H; Kebriaei, P; Shpall, E | 1 |
| Manzione, L; Olivieri, A | 1 |
| Bergeron, A; Bruzzoni-Giovanelli, H; Calvo, F; Levy, V; Meignin, V; Picard, C; Réa, D; Rousselot, P; Tamburini, J; Tazi, A | 1 |
| Schiffer, CA | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| Oestreicher, P | 2 |
| Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ | 1 |
| Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM | 1 |
| Bennett, KL; Colinge, J; Dürnberger, G; Fernbach, NV; Hantschel, O; Kaupe, I; Köcher, T; Planyavsky, M; Remsing Rix, LL; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Borthakur, G; Bruzzi, J; Cortes, J; Kantarjian, H; Munden, R; O'brien, S; Quintás-Cardama, A | 1 |
| Antolino, A; Berretta, S; Di Raimondo, F; Giustolisi, R; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C | 1 |
| Apperley, JF; De Melo, VA; Goldman, JM; Khorashad, JS; Marin, D; Milojkovic, D; Reid, AG | 1 |
| Holyoake, TL; Jørgensen, HG | 1 |
| Frame, D | 3 |
| Anand, M; Apperley, JF; Babb, A; de Lavallade, H; De Melo, V; Ghorashian, S; Goldman, JM; Kaeda, JS; Khorashad, JS; Marin, D; Mehta, P; Milojkovic, D; Olavarria, E; Reid, AG | 1 |
| Hochhaus, A | 2 |
| Fausel, C; Frame, D; Sessions, J | 1 |
| Fausel, C | 1 |
| Chemaly, RF; Torres, HA | 1 |
| Kujawski, L; Talpaz, M | 1 |
| Cuesta, B; Fernandez-Alonso, M; Galar, A; García-Muñoz, R; Merino, J; Moreno, C; Panizo-Morgado, E; Panizol, C; Ponz-Sarvisê, M; Prosper, F; Rodríguez-Otero, P; Rubio, M | 1 |
| Dobrovic, A; Kovalenko, S; McBean, M; Ritchie, DS; Seymour, JF; Westerman, DA | 1 |
| Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R | 1 |
| Steinberg, M | 1 |
| Hirano, I; Nakamura, S; Ohnishi, K; Okinaka, K; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y | 1 |
| Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T | 1 |
| Keam, SJ | 1 |
| Bjerrum, OW; Dufva, IH; Hasselbalch, HC; Stentoft, J | 1 |
| Apperley, J; Chaidos, A; Dannie, E; Davis, J; Gabriel, I; Goldman, J; Marin, D; Sorouri, J | 1 |
| Liu, XL; Zhang, S; Zhu, HQ | 1 |
| Apperley, JF; Bua, M; Chaidos, A; de Lavallade, H; Gabriel, IH; Goldman, JM; Khorashad, JS; Marin, D; Milojkovic, D; Olavarria, E; Punnialingam, S | 1 |
| Buchanan, S; Burley, SK; Corbin, AS; Deininger, MW; Eide, CA; Holme, K; Jessen, KA; Lewis, HA; O'Hare, T; Romero, RD; Tang, C; Tyner, JW; Wong, MJ | 1 |
| Cortes, J; Kantarjian, H | 2 |
| Blake, SJ; Bruce Lyons, A; Fraser, CK; Hayball, JD; Hughes, TP | 1 |
| Hantschel, O; Rix, U; Superti-Furga, G | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Corm, S; Countouriotis, AM; Deininger, M; Dombret, H; Ezzeddine, R; Goldberg, SL; Hochhaus, A; Hughes, T; Kantarjian, HM; Larson, RA; Lipton, JH; Müller, MC; Niederwieser, D; Roy, L; Shah, NP; Silver, RT; Stone, RM | 1 |
| Fandi, A; Lee, F; Voi, M | 1 |
| Barańska, M; Gniot, M; Iwoła, M; Komarnicki, M; Lewandowska, M; Lewandowski, K | 1 |
| DiPersio, JF; Ramirez, P | 1 |
| Bajel, A; Bassili, S; Seymour, JF | 1 |
| Atzeni, S; Azzena, L; Caocci, G; La Nasa, G; Ledda, A; Littera, R; Martorana, L; Orrù, N | 1 |
| Arnan, M; Brethon, B; Brito-Babapulle, F; Dombret, H; Duarte, RF; Eccersley, L; Elonen, E; Gruber, F; Hjorth-Hansen, H; Höglund, M; Klamova, H; Knutsen, H; Koskenvesa, P; Lee, FY; Lundán, T; Luo, R; Mustjoki, S; Paquette, R; Parikh, S; Porkka, K; Raffoux, E; Rimpiläinen, J; Smykla, R; Wild, R; Zwaan, CM | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J; Tam, CS | 1 |
| Efferth, T; Fabry, U; Glatte, P; Osieka, R | 1 |
| Bhattacharya, M; Bhattacharya, S; Biswas, J; Das, M; Ghosh, M; Ghosh, P; Gomes, A; Mitra, S; Murmu, N; Sur, P; Vedasiromoni, JR | 1 |
| Kass, L | 1 |
| Boyd, MR; Monks, A; Pittman, A; Scudiero, D; Skehan, P; Vistica, DT | 1 |
| Huismans, DR; Leyva, A; Pieters, R; Veerman, AJ | 1 |
160 review(s) available for thiazoles and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Paediatric chronic myeloid leukaemia: Is it really a different disease?
Topics: Antineoplastic Agents; Child; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatrics; Pyrimidines; Thiazoles | 2019 |
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Topics: Clinical Trials as Topic; Dasatinib; European Union; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2013 |
Management options for refractory chronic myeloid leukemia: considerations for the elderly.
Topics: Age Factors; Aged; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2013 |
[Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2013 |
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoadjuvant Therapy; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2013 |
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2013 |
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).
Topics: Antihypertensive Agents; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Dasatinib; Diabetes Mellitus; Humans; Hypertension; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Current diagnostic requirements in chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Guideline Adherence; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome | 2013 |
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Topics: Animals; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Dasatinib; Female; Genes, abl; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Ever-advancing chronic myeloid leukemia treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2014 |
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Large granular lymphocytosis during dasatinib therapy.
Topics: Antineoplastic Agents; Clone Cells; Colitis; Dasatinib; Familial Primary Pulmonary Hypertension; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes, Cytotoxic; Thiazoles; Thrombocytopenia | 2014 |
[Chronic myeloid leukemia: up-to-date management].
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Discovery; Drug Monitoring; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Molecular Targeted Therapy; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Dasatinib.
Topics: Animals; Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2014 |
[Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Topics: Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Pyrimidines; Thiazoles; Young Adult | 2014 |
Severe agitation in depression precipitated by dasatinib.
Topics: Azabicyclo Compounds; Dasatinib; Depression; Diagnosis, Differential; Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Psychomotor Agitation; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2014 |
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic | 2014 |
[Management of advanced stage chronic myeloid leukemia].
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2014 |
How I treat newly diagnosed chronic myeloid leukemia in 2015.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2015 |
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Drug Monitoring; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Nitriles; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thiazoles | 2015 |
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Topics: Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2015 |
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2008 |
Nilotinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Chemical; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Topics: Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
[Management of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
Targeted drugs in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles | 2008 |
[Chronic myeloid leukemia 2008].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2008 |
Imatinib and its successors--how modern chemistry has changed drug development.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2009 |
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Failure | 2009 |
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Topics: Clinical Trials as Topic; Contraindications; Dasatinib; Drug Interactions; Gastrointestinal Tract; Heart Diseases; Hematologic Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Pyrimidines; Thiazoles | 2009 |
New dosing schedules of dasatinib for CML and adverse event management.
Topics: Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Topics: Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Utilization; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Genetic; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Failure | 2009 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Costs and Cost Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles; Treatment Outcome | 2009 |
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Topics: Asian People; Clinical Trials as Topic; Dasatinib; Data Interpretation, Statistical; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Practical management of dasatinib for maximum patient benefit.
Topics: Antineoplastic Agents; Dasatinib; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
Topics: Administration, Oral; Benzamides; Carcinoma; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
New insights into small-molecule inhibitors of Bcr-Abl.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2011 |
Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Europe; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2009 |
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Topics: Algorithms; Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Water-Electrolyte Imbalance | 2009 |
[Clinical progress in chronic myelogenous leukemia].
Topics: Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dasatinib; Drug Discovery; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Comorbidity; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Mutation; Piperazines; Prognosis; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2010 |
Dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Thiazoles | 2010 |
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib: is it all in the dose?
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Pleural effusions due to dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles | 2010 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2007 |
First-line therapy for chronic myeloid leukemia: new horizons and an update.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Topics: Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2011 |
Allosteric inhibition of BCR-ABL.
Topics: Allosteric Regulation; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2011 |
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Topics: Benzamides; Clinical Trials as Topic; Congresses as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2011 |
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles | 2011 |
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
New drugs for chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2011 |
Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.
Topics: Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Chronic myelogenous leukemia: monitoring response to therapy.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Interpretation of cytogenetic and molecular results in patients treated for CML.
Topics: Benzamides; Cytogenetics; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Topics: Dasatinib; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transport Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Topics: Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Publication Bias; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2012 |
[TKI therapy for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2011 |
Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Effects of BCR-ABL inhibitors on anti-tumor immunity.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2011 |
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles | 2012 |
Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2012 |
Clinical trials in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2012 |
Chronic myelogenous leukemia for primary care physicians.
Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
[Current therapy of chronic myeloid leukemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom | 2012 |
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
Topics: Adult; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2010 |
Chronic myeloid leukemia: state of the art in 2012.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Leukemia: A highly malignant disease].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin | 2012 |
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2012 |
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2012 |
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Thiazoles | 2012 |
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2012 |
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
Topics: Dasatinib; Drug Eruptions; Exanthema; Guideline Adherence; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2013 |
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2013 |
Treating chronic myeloid leukemia: improving management through understanding of the patient experience.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Style; Patient Compliance; Patient Education as Topic; Piperazines; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Management of the new patient with CML in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Topics: Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2005 |
Chronic myelogenous leukemia.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic | 2005 |
Targeted CML therapy: controlling drug resistance, seeking cure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[Novel inhibitors of Bcr-Abl].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles | 2006 |
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Molecular targeting therapy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
What is new in chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Splenomegaly; Thiazoles | 2007 |
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
[New horizon of chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzene Derivatives; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2007 |
Dasatinib: a new step in molecular target therapy.
Topics: Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Adult; Benzamides; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
What's blasting off in CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles | 2007 |
Characterization of cancer stem cells in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2007 |
New strategies in controlling drug resistance.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Management of Bcr-Abl-positive leukemias with dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
New strategies in controlling drug resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles | 2007 |
Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Animals; Controlled Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
[Research advance on molecular genetics of CML blast crisis].
Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2008 |
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Overcoming kinase resistance in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Therapy options in imatinib failures.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2008 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
44 trial(s) available for thiazoles and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Topics: Animals; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription Factors | 2013 |
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles | 2013 |
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thiazoles | 2013 |
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Time; Treatment Outcome | 2014 |
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dasatinib; Dexamethasone; Doxorubicin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Vincristine; Young Adult | 2014 |
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Calcineurin Inhibitors; Cell Line, Tumor; Cyclosporine; Dasatinib; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Survival Analysis; Thiazoles | 2015 |
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Pyrimidines; RNA, Messenger; RNA, Neoplasm; ROC Curve; Thiazoles; Time Factors; Transcription, Genetic; Young Adult | 2015 |
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Philadelphia Chromosome; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2008 |
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult | 2009 |
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Incidence; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Pyrimidines; Retreatment; Thiazoles; Thrombocytopenia; Treatment Outcome | 2009 |
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2009 |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2009 |
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Treatment Outcome | 2010 |
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Hospitals, Pediatric; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Neoplasms; Patient Selection; Pediatrics; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Thiazoles; Treatment Outcome | 2011 |
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2011 |
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous | 2012 |
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemokines; Cytokines; Dasatinib; Female; Humans; Imatinib Mesylate; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2012 |
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Probability; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2012 |
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Thiazoles; Treatment Failure | 2007 |
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Topics: Administration, Oral; Adult; Aged; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; src-Family Kinases; Thiazoles | 2007 |
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2007 |
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles | 2007 |
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles | 2007 |
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pleural Effusion; Pyrimidines; Radiography; Risk Factors; Thiazoles; Treatment Failure | 2007 |
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Failure | 2008 |
American Society of Hematology annual meeting.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Dasatinib; Georgia; Hematology; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Pyrimidines; Societies, Medical; Survival Rate; Thiazoles; United States | 2008 |
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Topics: Adolescent; Adult; Aged; Animals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Cytogenetic Analysis; Dasatinib; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Monitoring; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Spinal Puncture; Survival Rate; Thiazoles; Treatment Outcome; Tumor Burden | 2008 |
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure | 2008 |
399 other study(ies) available for thiazoles and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Investigating the Activity of Indole-2-on Derivative Src Kinase Inhibitors Against Chronic Myeloid Leukemia Cells.
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2023 |
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pyrimidines; Spleen; Thiazoles | 2023 |
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Topics: Dasatinib; Humans; Interleukin-2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2023 |
Suppression of Musashi‑2 by the small compound largazole exerts inhibitory effects on malignant cells.
Topics: Adult; Aged; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Depsipeptides; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Mice; Middle Aged; Models, Molecular; Molecular Docking Simulation; Protein Conformation; RNA-Binding Proteins; Thiazoles; Up-Regulation | 2020 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2021 |
Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thiazoles; Up-Regulation; Veratrum Alkaloids | 2021 |
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoenzymes; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Thiazoles; Triazines | 2017 |
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Thiazoles | 2018 |
Chronic myeloid leukemia: advances in diagnosis and management.
Topics: Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2013 |
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Biological Transport; Bone Marrow Cells; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Nuclear Proteins; Osmolar Concentration; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2013 |
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles | 2013 |
Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2013 |
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Thiazoles; Vimentin | 2013 |
[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Topics: Benzamides; Dasatinib; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Chronic myeloid leukemia].
Topics: Dasatinib; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2012 |
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Dasatinib-induced nephrotic-range proteinuria.
Topics: Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nephrotic Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Blast Crisis; Central Nervous System Neoplasms; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2013 |
Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Bone Marrow; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Pyrimidines; Radiography; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2013 |
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Eruptions; Folliculitis; Hair Follicle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles | 2014 |
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; United Kingdom; Young Adult | 2013 |
T315I, more or less, predicts for major molecular response: the devil is in the details!
Topics: Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Pyrimidines; Thiazoles | 2013 |
Synthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrug.
Topics: Animals; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macaca mulatta; Male; Prodrugs; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2013 |
Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.
Topics: Adult; Dasatinib; Drug Eruptions; Female; Hair Diseases; Hair Follicle; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult | 2014 |
Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fertilization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
[Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
Topics: Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Thiazoles | 2013 |
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Dasatinib; Discoidin Domain Receptors; DNA Mutational Analysis; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Multiple Primary; Pyrimidines; Radiography; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Thiazoles; Treatment Outcome | 2013 |
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Biomarkers, Pharmacological; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Topics: Benzamides; Dasatinib; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Satisfaction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States | 2013 |
Reversible pre-capillary pulmonary hypertension due to dasatinib.
Topics: Dasatinib; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Thiazoles | 2014 |
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine | 2014 |
Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Dasatinib; Drug Administration Schedule; Drug Substitution; Humans; Hyperplasia; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Topics: Acute Kidney Injury; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pleural Effusion; Pyrimidines; Thiazoles | 2014 |
Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.
Topics: Aged; Dasatinib; Drug Eruptions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pemphigus; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
Topics: Clone Cells; Dasatinib; Female; Genes, abl; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Point Mutation; Pyrimidines; Thiazoles; Thrombocythemia, Essential; Translocation, Genetic | 2013 |
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Chronic myeloid leukaemia masquerading as primary myelofibrosis.
Topics: Biopsy; Blood Cell Count; Bone Marrow; Dasatinib; Diagnosis, Differential; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Phenotype; Piperazines; Pyrimidines; Thiazoles | 2013 |
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic | 2014 |
Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis.
Topics: Blast Crisis; Colitis; Colon, Descending; Dasatinib; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cluster Analysis; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Intercellular Signaling Peptides and Proteins; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptors, Erythropoietin; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Thiazoles | 2014 |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Vectors; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Retroviridae; Sorting Nexins; Thiazoles; Transfection | 2014 |
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Aged; Benzamides; Capsule Endoscopy; Dasatinib; Drug Substitution; Endoscopes, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2015 |
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; HLA-A2 Antigen; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; WT1 Proteins | 2014 |
NKT cell-infiltrating aseptic meningitis on the central nervous system in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib.
Topics: Central Nervous System; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meningitis, Aseptic; Middle Aged; Natural Killer T-Cells; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Middle Aged; Neoplasm Grading; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2014 |
Chronic myelogenous leukemia presenting with bilateral optic disc neovascularization.
Topics: Combined Modality Therapy; Dasatinib; Fluorescein Angiography; Humans; In Situ Hybridization, Fluorescence; Laser Coagulation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Magnetic Resonance Imaging; Male; Middle Aged; Optic Disk; Protein Kinase Inhibitors; Pyrimidines; Retinal Neovascularization; Thiazoles; Visual Acuity; Vitrectomy | 2014 |
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Pneumocystis carinii; Pneumonia, Pneumocystis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Topics: ADP-ribosyl Cyclase 1; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Sirtuin 1; Thiazoles; Tretinoin | 2014 |
[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
Topics: Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2014 |
Toward therapeutic effects evaluation of chronic myeloid leukemia drug: electrochemical platform for caspase-3 activity sensing.
Topics: Apoptosis; Biosensing Techniques; Caspase 3; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Electrochemical Techniques; Equipment Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Optic coherence tomography of foveal hemorrhage associated with chronic myelogenous leukemia.
Topics: Adult; Dasatinib; Female; Fovea Centralis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retinal Hemorrhage; Thiazoles; Tomography, Optical Coherence; Vision Disorders; Visual Acuity | 2015 |
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Topics: Aminosalicylic Acids; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Luciferases; Molecular Docking Simulation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Sulfonamides; Thiazoles | 2015 |
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.
Topics: Base Sequence; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles; Translocation, Genetic | 2014 |
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Dasatinib; Drug Substitution; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pulmonary Alveolar Proteinosis; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2014 |
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Topics: Adolescent; Adult; Aged; Dasatinib; Databases, Factual; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2014 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinations; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Protein Kinase Inhibitors; Pyrimidines; Tegafur; Thiazoles | 2014 |
[Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].
Topics: Acute Disease; Central Nervous System; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Pyrimidines; Thiazoles | 2014 |
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Topics: Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Dasatinib; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Patient Care; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; United States | 2015 |
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Topics: Adult; Antineoplastic Agents; Australia; Benzamides; Canada; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Therapy Management; Middle Aged; Piperazines; Practice Patterns, Physicians'; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2015 |
Basophilic blast phase of chronic myelogenous leukemia.
Topics: Adult; Basophils; Blast Crisis; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles; Treatment Failure | 2014 |
A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy.
Topics: Antineoplastic Agents; Dasatinib; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Spectrometry, Fluorescence; Thiazoles | 2015 |
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.
Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moxifloxacin; Peritonitis, Tuberculous; Protein Kinase Inhibitors; Pyrazinamide; Pyrimidines; Thiazoles | 2015 |
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Cardiovascular Diseases; Dasatinib; Databases, Factual; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Lung Diseases; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration; Young Adult | 2015 |
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Child; Chronic Disease; Dasatinib; Disease Progression; Female; Flow Cytometry; Follow-Up Studies; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oxazines; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Syk Kinase; Thiazoles; Tumor Cells, Cultured; Young Adult | 2015 |
[Dasatinib-related pneumonia? An example of pharmacovigilance survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Pharmacovigilance; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Thiazoles; Tomography, X-Ray Computed; Vincristine | 2015 |
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Topics: Autoantigens; Cell Line, Tumor; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Proto-Oncogene Proteins c-myc; RNA Interference; RNA, Small Interfering; Thiazoles | 2015 |
Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Transcriptome | 2015 |
Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
Topics: Adult; Antineoplastic Agents; Dasatinib; Drug Substitution; Echocardiography; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.
Topics: Acute Disease; Adolescent; Colitis; Dasatinib; Gastrointestinal Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Exons; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Pyrimidines; RNA, Messenger; Sequence Analysis, DNA; Thiazoles | 2015 |
Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Topics: Aged; Dasatinib; Dyspnea; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2015 |
BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Topics: Antineoplastic Agents; Blast Crisis; Dasatinib; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
[CHRONIC MYELOID LEUKEMIA IN A YOUNG MALE PRESENTING WITH BILATERAL CALF PAIN DUE TO LEUKOSTASIS].
Topics: Allopurinol; Bone Marrow Examination; Dasatinib; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hydroxyurea; Leg; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukostasis; Male; Myalgia; Ophthalmoscopy; Philadelphia Chromosome; Pyrimidines; Retinal Hemorrhage; Thiazoles; Treatment Outcome; Young Adult | 2015 |
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment.
Topics: Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Treatment-free remission after stopping second-line dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
The Authors Respond.
Topics: Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Colitis; Dasatinib; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Thiazoles | 2018 |
2-Aminoxazole and 2-Aminothiazole Dasatinib Derivatives as Potent Inhibitors of Chronic Myeloid Leukemia K562 Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxazoles; Structure-Activity Relationship; Thiazoles | 2016 |
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Mice; Pancreatic Neoplasms; Structure-Activity Relationship; Thiazoles | 2016 |
Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature.
Topics: Colitis; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2016 |
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Temperature; Thiazoles; Tumor Cells, Cultured | 2008 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Dasatinib-induced acute hepatitis.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2008 |
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Cell Separation; Dasatinib; Dogs; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles | 2008 |
Dasatinib-induced lupus.
Topics: Aged; Autoantibodies; Autoimmunity; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Dasatinib; Feasibility Studies; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2008 |
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2008 |
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles | 2008 |
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles | 2008 |
Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Poly(ADP-ribose) Polymerases; Pyrimidines; Signal Transduction; Thiazoles | 2008 |
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles | 2009 |
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Topics: Benzamides; Bone Marrow; Cell Death; Cell Line, Tumor; Culture Media, Conditioned; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; STAT3 Transcription Factor; Thiazoles | 2008 |
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Topics: Adenosine Triphosphate; Benzamides; Cell Line; Cloning, Molecular; Collagen; Dasatinib; Discoidin Domain Receptor 1; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structural Homology, Protein; Thiazoles | 2008 |
Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Topics: Adenylyl Imidodiphosphate; Animals; Apoenzymes; B-Lymphocytes; Catalytic Domain; Crystallography, X-Ray; Dasatinib; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Dasatinib; Echocardiography; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2009 |
In vitro anti-leukaemia activity of sphingosine kinase inhibitor.
Topics: Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors | 2009 |
Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2009 |
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Topics: Apoptosis; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2008 |
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; RNA, Messenger; RNA, Small Interfering; src-Family Kinases; Thiazoles; Transfection | 2008 |
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Topics: Antineoplastic Agents; Cell Lineage; Dasatinib; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Natural Killer T-Cells; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2009 |
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.
Topics: Animals; Bone Marrow; Cell Proliferation; Cells, Cultured; Dasatinib; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Mice; Myeloid Cells; Osteoclasts; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; src-Family Kinases; Thiazoles | 2009 |
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Topics: Child, Preschool; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Transplantation, Homologous | 2009 |
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Dasatinib; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles | 2009 |
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Topics: Antineoplastic Agents; Benzamides; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Thiazoles | 2009 |
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations.
Topics: Adult; Blast Crisis; Brain Neoplasms; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Radiography; Thiazoles | 2009 |
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Cohort Studies; Colitis; Dasatinib; Female; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Pleurisy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Thiazoles | 2009 |
The toxicities of modern targeted therapies: learning from the price of progress.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; ErbB Receptors; Hemorrhage; Humans; Imatinib Mesylate; Interdisciplinary Communication; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; Skin; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Calcium; Cell Death; Cell Line, Tumor; Chloroquine; Dasatinib; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Mice; Mice, Inbred C3H; Microtubule-Associated Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; Thiazoles; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2009 |
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Hair Color; Humans; Hypopigmentation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; src-Family Kinases; Thiazoles | 2009 |
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Dasatinib; Down-Regulation; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Interleukin-8; Lectins, C-Type; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2008 |
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles; Time Factors; Young Adult | 2009 |
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Topics: Benzamides; Blood Coagulation; Blood Platelet Disorders; Dasatinib; Health; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles | 2009 |
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Dasatinib; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Thiazoles; Treatment Failure | 2009 |
Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Chronic myelogenous leukaemia market.
Topics: Benzamides; Dasatinib; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines; Thiazoles | 2009 |
Dasatinib: for some difficult cases of adult leukaemia.
Topics: Adult; Clinical Trials as Topic; Drug Approval; Europe; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orphan Drug Production; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Pyrimidines; Thiazoles | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML.
Topics: Adult; Blast Crisis; Dasatinib; Female; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Pyrimidines; Thiazoles | 2010 |
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Spain; Survival Rate; Thiazoles | 2009 |
Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Delivery, Obstetric; Female; Humans; Imatinib Mesylate; Interferons; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Thiazoles | 2009 |
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2009 |
Optimizing first-line therapy for patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
New directions in the treatment of imatinib failure and/or resistance.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Topics: Butadienes; Dasatinib; Databases, Protein; Epidermal Growth Factor; Fusion Proteins, bcr-abl; HeLa Cells; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridines; Pyrimidines; Signal Transduction; Thiazoles; Up-Regulation | 2009 |
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; Signal Transduction; Thiazoles | 2009 |
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.
Topics: Annexin A5; Apoptosis; Cell Division; Cell Survival; Cells, Cultured; Dasatinib; Hematopoietic Stem Cells; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfluidics; Microscopy, Fluorescence; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles | 2009 |
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Topics: Apoptosis; Dasatinib; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2009 |
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Basophils; Dasatinib; Female; Flow Cytometry; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Middle Aged; Proteome; Pyrimidines; Thiazoles | 2009 |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2009 |
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2009 |
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Topics: Amino Acid Substitution; Antineoplastic Agents; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylalanine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Lasker Awards and papal portraiture: turning fields upside down.
Topics: Awards and Prizes; Benzamides; Cellular Reprogramming; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orientation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Topics: Adult; Benzamides; Cohort Studies; Cytogenetic Analysis; Dasatinib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Dasatinib-induced pleural effusions: a lymphatic network disorder?
Topics: Adult; Aged; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; Ear Diseases; Fusion Proteins, bcr-abl; Humans; Keratoacanthoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Pyrimidines; Radiotherapy; Scalp; Thiazoles; Tongue Neoplasms; Vocal Cords | 2010 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2010 |
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Hematology: dasatinib regimens for patients with chronic myeloid leukemia.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
Topics: Clinical Trials as Topic; Dasatinib; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
p38 in chronic myelogenous leukemia: a target and a possible biomarker.
Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Signal Transduction; Thiazoles | 2009 |
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Topics: Adenine; Animals; Benzamides; Binding Sites; Cell Line; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.
Topics: Antineoplastic Agents; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.
Topics: Blast Crisis; Cord Blood Stem Cell Transplantation; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Topics: Chronic Disease; Combined Modality Therapy; Dasatinib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Sclerosis; Severity of Illness Index; Thiazoles; Young Adult | 2010 |
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Topics: Antigens, CD34; Apoptosis; Blotting, Western; Cytokines; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Janus Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2010 |
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Topics: Animals; Benzamides; beta Catenin; Cell Hypoxia; Cell Line, Tumor; Dasatinib; Humans; Imatinib Mesylate; Lactoylglutathione Lyase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Heterologous | 2010 |
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Topics: Aluminum Silicates; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles | 2010 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Topics: Aged; Anti-Inflammatory Agents; Colonic Diseases; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Subcutaneous Tissue; Thiazoles; Thymosin; Treatment Outcome; Ulcer | 2010 |
Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dasatinib; Dose-Response Relationship, Drug; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Primary Myelofibrosis; Pyrimidines; Thiazoles | 2010 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
[Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytomegalovirus Infections; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2010 |
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.
Topics: Antigens, CD34; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dasatinib; Fetal Blood; Humans; Infant, Newborn; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cells; Stromal Cells; Thiazoles; Time Factors | 2010 |
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dasatinib; Female; Humans; Leukemia, Large Granular Lymphocytic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Lymphocytosis; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aniline Compounds; Case-Control Studies; Centrosome; Dasatinib; Female; Fibroblasts; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2010 |
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CD8-Positive T-Lymphocytes; Clonal Anergy; Clone Cells; Cytomegalovirus; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Thiazoles; Virus Activation; Young Adult | 2010 |
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Pyrimidines; Thiazoles | 2010 |
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Topics: Chromosomes, Human, Pair 7; Dasatinib; Female; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Monosomy; Mutation; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Thiazoles | 2010 |
Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fertilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Topics: Antineoplastic Agents; Benzamides; Chromosome Breakpoints; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2010 |
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Biosensing Techniques; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fluorescence; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Calcium; Cell Proliferation; Cyclosporine; Cytokines; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Wnt Proteins | 2010 |
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Drug Costs; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Sweden; Thiazoles; Treatment Outcome | 2010 |
Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Topics: Adolescent; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Pyrimidines; Thiazoles | 2010 |
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Topics: Adolescent; Adult; Aged; Clone Cells; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Neoplasm; Thiazoles; Young Adult | 2010 |
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Antigens, Surface; Benzamides; Blood Cells; Bone Marrow Cells; Cell Count; Cytotoxicity, Immunologic; Dasatinib; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immune System; Immunologic Memory; Immunophenotyping; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2010 |
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; Thiazoles | 2010 |
Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Aged; Biopsy; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Separation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Biosensing Techniques; Cells, Cultured; Chlorocebus aethiops; Computer Systems; COS Cells; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorescence Resonance Energy Transfer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines; Thiazoles; Time Factors | 2010 |
Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.
Topics: Adult; Colon; Dasatinib; Female; Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ulcer | 2010 |
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2010 |
Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Prevalence; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland | 2010 |
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2011 |
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzamides; Blast Crisis; Clofarabine; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Homologous | 2010 |
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transcription, Genetic | 2011 |
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Algorithms; Ambulatory Care; Antineoplastic Agents; Cohort Studies; Comorbidity; Dasatinib; Databases, Factual; Female; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Pyrimidines; Retrospective Studies; Thiazoles | 2010 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
[Effect of low-dose dasatinib in an elderly patient with chronic myelogenous leukemia (CML)].
Topics: Aged; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles | 2011 |
[Chronic myeloid leukemia and targeted therapies: too many choices?].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Protocols; Benzamides; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Thiazoles; Withholding Treatment | 2011 |
[A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosomes, Human, Pair 3; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunity, Innate; Immunoglobulins; Immunologic Factors; Interferon-alpha; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles; Treatment Outcome | 2010 |
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Role of Pten in leukemia stem cells.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles | 2010 |
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Topics: Benzamides; Child; Dasatinib; Diseases in Twins; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Panniculitis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Skin; Thiazoles | 2011 |
Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Pyrimidines; Safety-Based Drug Withdrawals; Thiazoles | 2011 |
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Topics: Aged; Dasatinib; Diuretics; Drug Administration Schedule; Female; Furosemide; Glucocorticoids; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Severity of Illness Index; Thiazoles; Turkey | 2011 |
Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Disease-Free Survival; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Medical Records; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia.
Topics: Biomarkers, Tumor; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Netherlands; Protein Kinases; Pyrimidines; Thiazoles | 2011 |
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Topics: Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Topics: Apoptosis; Caspase 3; Cell Line; Ceramides; Dasatinib; Dose-Response Relationship, Drug; Glucosyltransferases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Oxidoreductases; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Duplication; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Topics: Blast Crisis; Bone Marrow; Dasatinib; Femur; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; Orbital Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2011 |
Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cross Reactions; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Topics: Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Topics: Aged; Dasatinib; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
Topics: Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles | 2011 |
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles; Vault Ribonucleoprotein Particles | 2011 |
Dasatinib for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Dasatinib; Dose-Response Relationship, Drug; Enzyme Assays; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Thiazoles | 2010 |
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Blood Pressure; Dasatinib; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pulmonary Medicine; Pyrimidines; Thiazoles; Treatment Outcome; Ventricular Dysfunction, Right | 2011 |
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Topics: Aged; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2011 |
Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.
Topics: Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Dasatinib; Diagnosis, Differential; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Multiple Primary; Pyrimidines; Recurrence; Remission Induction; Skin Neoplasms; Thiazoles; Tumor Burden | 2011 |
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Topics: Apoptosis; Dasatinib; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2012 |
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
Topics: Adult; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Thiazoles | 2011 |
Whistleblowers.
Topics: Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2011 |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2011 |
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; Remission, Spontaneous; Thiazoles; Time Factors | 2012 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |
[Roles of the 2nd generation TKIs for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2011 |
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib.
Topics: Adolescent; Blast Crisis; Bone Marrow Transplantation; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dasatinib; Fatal Outcome; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles | 2011 |
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Pyrimidines; Thiazoles | 2011 |
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
Topics: Antineoplastic Agents; Benzamides; Calibration; Cells, Cultured; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Limit of Detection; Mass Spectrometry; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; Reproducibility of Results; Thiazoles | 2012 |
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nizatidine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2012 |
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; International Classification of Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome; Young Adult | 2012 |
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Young Adult | 2011 |
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HEK293 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Nuclear Proteins; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles | 2012 |
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Topics: Animals; Benzamides; Cell Communication; Cell Differentiation; Collagen; Culture Media, Conditioned; Dasatinib; Drug Combinations; Endocytosis; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; K562 Cells; Laminin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Nanotubes; Neovascularization, Physiologic; Piperazines; Proteoglycans; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors | 2012 |
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Topics: Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles | 2012 |
Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome | 2012 |
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Nucleus; Cells, Cultured; Cyclin D1; Cytokines; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleimides; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2012 |
Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cytomegalovirus Infections; Dasatinib; Databases, Factual; Female; Humans; Infections; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pyrimidines; Research Design; Risk Factors; Thiazoles; Treatment Outcome | 2012 |
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Topics: Adult; Benzamides; Comorbidity; Dasatinib; Disease Management; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; South Africa; Thiazoles; Treatment Outcome | 2011 |
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; Asia, Southeastern; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
Topics: Active Transport, Cell Nucleus; bcl-X Protein; Cell Nucleus; Cytoplasm; Dasatinib; Fusion Proteins, bcr-abl; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfluidic Analytical Techniques; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2012 |
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Delivery of Health Care; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United Kingdom | 2012 |
A dramatic fetal outcome following transplacental transfer of dasatinib.
Topics: Dasatinib; Female; Fetus; Humans; Hydrops Fetalis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
NICE backs leukaemia drug after manufacturer drops price.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Nude; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oxazoles; Phosphorylation; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2012 |
Double-edged sword of the new cancer therapeutics.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome | 2012 |
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States | 2012 |
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction | 2012 |
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Choice Behavior; Dasatinib; Health Services Needs and Demand; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Risk Assessment; Risk Factors; Thiazoles | 2012 |
CML treatment in Asia-Pacific region.
Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2012 |
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dasatinib; Feeder Cells; Hedgehog Proteins; Humans; Intracellular Space; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Thiazoles; Transcription Factors; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2012 |
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy.
Topics: Autophagy; Cell Death; Cell Line, Tumor; Clarithromycin; Dasatinib; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2013 |
H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.
Topics: Female; Histamine H2 Antagonists; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proton Pump Inhibitors; Pyrimidines; Thiazoles | 2012 |
Re: Ulcickas Yood M, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012, 28(2): 213-19.
Topics: Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Pyrimidines; Thiazoles | 2012 |
MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Topics: Antineoplastic Agents; Benzamides; beta-Globins; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Erythroid Cells; Gene Expression; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; S-Phase Kinase-Associated Proteins; Thiazoles | 2013 |
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles | 2012 |
Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytomegalovirus; Dasatinib; Female; Gene Rearrangement, T-Lymphocyte; Humans; Immunophenotyping; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Thiazoles; Treatment Outcome; Virus Activation; Young Adult | 2012 |
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Topics: Aged; Cytogenetics; Dasatinib; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2013 |
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, KIR; Thiazoles | 2012 |
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Gene Expression Profiling; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Receptors, KIR; Thiazoles | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; RNA, Small Interfering; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles | 2012 |
Dasatinib in chronic myeloid leukemia: a limited Indian experience.
Topics: Adult; Dasatinib; Female; Humans; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
10 years of progress in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles | 2012 |
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Topics: Dasatinib; Echocardiography; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Thiazoles; Treatment Outcome; Vasodilator Agents; Withholding Treatment | 2012 |
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2012 |
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; Thiazoles; Vincristine | 2012 |
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
Topics: Antigens, CD34; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Substrate Specificity; Thiazoles | 2013 |
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Topics: Adult; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dasatinib; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Interleukin-2; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; Stimulation, Chemical; T-Lymphocyte Subsets; Thiazoles; Zoledronic Acid | 2013 |
[Treatment for de novo chronic myeloid leukemia in chronic phase].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Treatment of imatinib-intolerant or -resistant CML patients].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult | 2013 |
Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System; Dasatinib; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2013 |
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2012 |
As leukemia options grow, drugs jockey to be first-line therapies.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2013 |
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.
Topics: Animals; Benzamides; Cluster Analysis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Spectroscopy, Fourier Transform Infrared; Thiazoles; Tumor Cells, Cultured | 2013 |
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
Antineoplastic effect of new boron compounds against leukemic cell lines and cells from leukemic patients.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Division; Guanidines; HL-60 Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Tetrazolium Salts; Thiazoles; Thymidine; U937 Cells | 2002 |
Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Pyrimidines; Thiazoles | 2004 |
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Cell Line; Clinical Trials, Phase I as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutation; Piperazines; Protein Conformation; Pyrimidines; Thiazoles; Transfection | 2004 |
New generation leukaemia drugs are on their way.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2004 |
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Topics: Apoptosis; Blast Crisis; Blotting, Western; Fusion Proteins, bcr-abl; Humans; In Situ Nick-End Labeling; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2004 |
Oral BMS-354825 rescues Gleevec-resistant CML.
Topics: Administration, Oral; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Two new agents effective in Gleevec-resistant CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2005 |
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genetic Vectors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Phosphotyrosine; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Stem Cells; Thiazoles; Time Factors | 2005 |
Loss of response to imatinib: mechanisms and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Failure | 2005 |
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Topics: Aurora Kinases; Benzamides; Catalytic Domain; Crystallography; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2006 |
Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Dosage; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2006 |
Dasatinib: BMS 354825.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2006 |
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Topics: Animals; Benzamides; Blast Crisis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
Circumventing resistance to kinase-inhibitor therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Tyrosine kinase inhibitors: the next generation.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Paracentesis; Pleural Effusion; Pleurodesis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Glivec and beyond.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2006 |
Dasatinib.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Dasatinib; Drug Approval; Guideline Adherence; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2006 |
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured; Vorinostat | 2006 |
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2006 |
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Nuclear Proteins; Predictive Value of Tests; Pyrimidines; Structure-Activity Relationship; Thiazoles; Time Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Dasatinib (Sprycel) for CML and Ph + ALL.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Dasatinib.
Topics: Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Topics: Adolescent; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Topics: Apoptosis; bcl-X Protein; Cell Count; Cell Survival; Cyclin D1; Dasatinib; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphotyrosine; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2007 |
Dasatinib is effective in imatinib-resistant CML.
Topics: Benzamides; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; United Kingdom | 2007 |
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells; Thiazoles; Treatment Outcome | 2007 |
Paradoxical proliferative potential of iron (II) sulphate on cancer cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay.
Topics: Breast Neoplasms; Carcinoma; Cell Proliferation; Colony-Forming Units Assay; Humans; Iron Compounds; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Sulfates; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2007 |
Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
Topics: Brain; Central Nervous System Neoplasms; Dasatinib; Humans; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2007 |
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Topics: Adult; Aged; Bronchoalveolar Lavage Fluid; Chest Pain; Cough; Dasatinib; Dyspnea; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lymphocytes; Male; Middle Aged; Myeloid Cells; Neutrophils; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Radiography; Thiazoles | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
Drugs offer new hope for patients with CML who are resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine | 2007 |
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured | 2007 |
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Topics: Benzamides; Dasatinib; Discoidin Domain Receptor 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinone Reductases; Receptor Protein-Tyrosine Kinases; Thiazoles | 2007 |
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2007 |
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
Topics: Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Chronic myeloid leukemia. Introduction.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Leukemia. Q&A highlights.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pyrimidines; Thiazoles | 2007 |
Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?
Topics: Cytomegalovirus Infections; Dasatinib; Herpesvirus 6, Human; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Parvoviridae Infections; Parvovirus B19, Human; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Virus Activation | 2007 |
Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
Topics: Acute Disease; Cytomegalovirus; Dasatinib; Female; Herpesvirus 6, Human; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Virus Activation | 2007 |
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Thiazoles | 2008 |
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2008 |
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Topics: Adult; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell Proliferation; Cells, Cultured; Chromones; Colony-Forming Units Assay; Dasatinib; DNA Primers; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thiazoles; Transfection | 2008 |
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2008 |
[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Autoimmune Diseases; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pleural Effusion, Malignant; Pyrimidines; Retrospective Studies; Thiazoles | 2008 |
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Dasatinib suppresses in vitro natural killer cell cytotoxicity.
Topics: Cytotoxicity, Immunologic; Dasatinib; Humans; Jurkat Cells; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; Thiazoles | 2008 |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Topics: Adult; Benzamides; Dasatinib; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retinal Diseases; Thiazoles | 2008 |
Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Topics: Aged; Dasatinib; Gynecomastia; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Selective Estrogen Receptor Modulators; Tamoxifen; Thiazoles; Treatment Outcome | 2008 |
Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.
Topics: Apoptosis; Caffeine; Carboplatin; Cluster Analysis; Coloring Agents; Daunorubicin; Drug Resistance, Neoplasm; Flow Cytometry; G2 Phase; Gamma Rays; Gene Expression Regulation, Leukemic; Glutathione; GTP-Binding Proteins; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Multivariate Analysis; Oncogene Proteins v-fos; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; ras Proteins; S Phase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |
Boron compounds against human leukemic cells.
Topics: Apoptosis; Boron Compounds; Cell Division; DNA, Neoplasm; Guanidines; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tetrazolium Salts; Thiazoles; Thymidine; Tumor Cells, Cultured; U937 Cells | 2001 |
Basic blue 54: a new colorant for monocytes.
Topics: Azo Compounds; Chromatin; Cytoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukocytes; Monocytes; Neutrophils; Staining and Labeling; Thiazoles | 1992 |
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production.
Topics: Carcinoma, Renal Cell; Cell Division; Cell Line; Cell Survival; Coloring Agents; Drug Screening Assays, Antitumor; Formazans; Glucose; Humans; Kidney Neoplasms; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NAD; NADP; Tetrazolium Salts; Thiazoles | 1991 |
Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia.
Topics: Antineoplastic Agents; Cell Survival; Child; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1989 |